The efficacy of furosemide in reducing methotrexate toxicity in patients suffering from Acute lymphoblastic leukemia

Efficacy of intravenous injection Furosemide in reduction of Methotrexate toxicity in children with Acute Lymphoblastic leukemia on high dose methotrexate therapy -A Single centre open-label randomised control Trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062267

Enrollment

160

Registered

2024-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]

Interventions

Intervention1: Giving Inj Furosemide: Giving inj Furosemide to Patients diagnosed to have acute lymphoblastic leukemia on high dose methotrexate therapy Dose 1mg/kg Frequency - every 6 th hourly Ro

Eligibility

Inclusion criteria

Inclusion criteria: Children diagnosed to have acute lymphoblastic leukemia on high dose methotrexate therapy.

Exclusion criteria

Exclusion criteria: children with chronic kidney disease,Chronic liver disease

Design outcomes

Primary

Measure	Time frame
serum methotrexate levelsTimepoint: 48 hours after starting high dose methotrexate Therapy.	—

Secondary

Measure	Time frame
hemoglobin levels,ANC levels ,Liver enzymes, urea and creatinineTimepoint: 48 hrs	—

Countries

India

Contacts

Public ContactShrinidhi Suresh Ambore

AIIMS Patna

cmkumar@aiimspatna.org9810730206

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026